Xeno Laboratories Testosterone Injectable Esters Lineup
Out of stock
Injection · 5.4 mg/ml · 10 ml
Xeno Labs Solaris combines clenbuterol and yohimbine at 5.4 mg/ml in a 10 ml injectable vial, used in the closing weeks of a cut when stubborn fat stops moving. Available as Xeno Labs Solaris 5.4 mg/ml.
Supplied as a 10 ml sealed vial, GMP-manufactured and HPLC-verified per batch with the Certificate of Analysis on file.
Xeno Labs Solaris is an injectable blend of clenbuterol and yohimbine at 5.4 mg/ml, supplied in a 10 ml vial. It is built for the closing weeks of a cut, when diet and training have stopped freeing stubborn fat. Clenbuterol drives the metabolic side, and the alpha-2 block from the yohimbine is what the hardest deposits respond to. It runs beside thyroid hormone such as Xeno T3 or Xeno T4.
Clenbuterol is a selective beta-2 adrenergic agonist. It activates those receptors in fat and muscle tissue, which raises resting energy use and heat production. Yohimbine blocks presynaptic alpha-2 adrenergic receptors, so more norepinephrine is released from nerve endings and fat cells receive a stronger fat-releasing signal. Both act on the sympathetic nervous system, which is why the pair lifts heart rate and blood pressure and why the dose is built up slowly. A tablet alternative is Xeno Clenbuterol.
Solaris is injected, so the daily volume and the injection site are set by the prescriber, and common community schedules run the blend in short blocks with a taper rather than continuously. The first days are run at the low end and the amount is stepped up only if the response stays tolerable. High clenbuterol exposure is linked to tachycardia, hand tremor, low blood potassium and arrhythmias, so the block is kept short and the climb slow. Helios is the reference point for this family of blends. Follow your prescribing physician's instructions.
Each lot is produced under GMP conditions and assayed by HPLC before release, with the result tied to the batch code on the vial. Match the vial and the code to the paperwork on arrival, and store the vial dry, at room temperature and out of direct light.
Prescription medicine: consult a healthcare professional before use.
| Trade Name | Solaris |
| Generic Name | Clenbuterol and Yohimbine |
| Manufacturer | Xeno Labs |
| Dosage | 5.4 mg/ml |
| Package | 10 ml vial |
| Drug Class | Beta-2 agonist and alpha-2 blocker |
| Administration | Injection |
| Storage | Dry, room temperature, away from light |
| Prescription Status | Prescription medicine |
| Verification | Third-party HPLC per batch, COA on file |
| Shipping | U.S. domestic and international |
Consult a healthcare professional before any cycle. When a stack includes compounds that suppress natural testosterone, PCT is required. Dosages reflect community protocols.
Before you ask
It is a 10 ml injectable blend of clenbuterol, a beta-2 adrenergic agonist, and yohimbine, an alpha-2 adrenergic blocker, at 5.4 mg/ml. Cutting plans use it in the closing weeks, when a long deficit has pushed metabolic rate down and the scale has stalled. Every lot is analysed per batch with the report on file.
Because it is injected, the daily volume and site are set by the prescriber. Common community schedules run the blend in short blocks with a taper: the first days at the low end, then a step up only while the response stays tolerable, and a step down before the block ends. Splitting the week rather than running it continuously keeps the receptors and the heart from being pushed.
Solaris is an injectable blend, so it carries yohimbine alongside the clenbuterol and delivers both in one measured volume. An oral tablet contains clenbuterol alone and is taken in split doses through the day. The alpha-2 block from the yohimbine is the practical difference, since it targets the fat-release signal that clenbuterol alone does not touch.
Clenbuterol toxicity is sympathomimetic: tachycardia, chest tightness, hand tremor, agitation, low blood potassium, raised blood sugar and cardiac arrhythmias, with sweating and poor sleep at lower exposure. Yohimbine raises blood pressure and can trigger anxiety, tremor and restlessness, and it reverses the effect of alpha-2 drugs such as clonidine. Anyone with a heart condition, high blood pressure or an arrhythmia stays away from the blend.
No for the blend itself. Clenbuterol and yohimbine do not suppress natural testosterone, so a Solaris-only block needs no post-cycle therapy. When a steroid is stacked with it, PCT is required - Nolvadex 20 mg daily for 4 weeks, with Clomid as the alternative, because the steroid suppresses natural testosterone.
Yes. Xeno Labs Solaris 5.4 mg/ml is stocked here as a 10 ml vial with U.S. domestic and international delivery, and this page shows current availability and restocks. Each batch is GMP-manufactured and HPLC-verified, with the Certificate of Analysis held on file for the batch number.
Be the first to share your experience with Xeno Labs Solaris 5.4 mg/ml Clenbuterol and Yohimbine Injection
Log in to write a reviewComplete the cycle
Out of stock
Out of stock
Out of stock